AI-Powered TCM at Tianjin Da Ren Tang: How Zhang Boli's 180 Million Yuan Modernization Project Is Reshaping Traditional Chinese Medicine

A century-old herbal pharmacy in Tianjin just bet 180 million yuan that artificial intelligence can do what human pharmacists have done since 1914 — only at 102°C precision, with a 15% energy saving, and a tongue-diagnosis report in seconds.

By China Hospitals Guide Editorial Team · Published 6 July 2026 · 6 min read · Categories: Traditional Chinese Medicine · AI in Medicine · Integrative Medicine

Hussain Dawood, the chairman of Pakistan's Engro Corporation, did not walk out with the other 300 delegates when the Tianjin 2026 Global Business Leaders Roundtable closed in March. He waited behind. His wife has chronic high blood pressure. The Pakistani physicians had tried the usual roster of antihypertensives with limited effect, and Dawood — whose family has long trusted Eastern therapeutic philosophies — wanted a private consultation with the attending experts from Tianjin Pharmaceutical Da Ren Tang Group, the 112-year-old herbal house that hosted the roundtable.

The anecdote, reported by China Daily on 3 July 2026, frames the new face of traditional Chinese medicine for international patients. The wisdom of TCM lies in its personalised approach, said Wang Lei, Da Ren Tang's chairwoman, at the same event. Even for the most common cold, TCM recognises that some people catch it due to "heat" while others due to "cold". When TCM spreads to different countries, it must also adapt to the local climate and physical characteristics for effective diagnosis and treatment. That tension between age-old personalisation and global scale is exactly what is driving a massive technological overhaul within China's TCM sector — and Tianjin is the testbed.

Why an academician of engineering is redesigning an herbal pharmacy

Zhang Boli is not a typical pharmaceutical executive. A clinician who spent four decades studying how Chinese herbal formulas interact with the immune system (his early-2000s work on the Lianhua Qingwen formula during SARS became a national reference), he holds the title of academician of the Chinese Academy of Engineering and is the most senior TCM researcher advising the State Administration of Traditional Chinese Medicine. The 180 million yuan project is his bet that the bottleneck for TCM's global growth is not cultural acceptance — it is industrial precision.

The bottleneck he is targeting is the decoction step — the gentle, sustained boiling that extracts the active compounds from raw herb bundles. Done correctly, it is the soul of a TCM prescription. Done sloppily, it is where most of the alkaloid, flavonoid, and polysaccharide payload is lost. Human pharmacists, watching bubble size in a copper pot, hold temperature within roughly ±10°C of target. The robotic system holds it to within a fraction of a degree, day after day, batch after batch. For a hospital that dispenses 10,000 prescriptions a month, the cumulative quality gain is the difference between artisanal and pharmaceutical.

This matters for international patients because the consistency gap is what regulatory agencies abroad have flagged for years. The European Food Safety Authority and Australia's Therapeutic Goods Administration have both approved Da Ren Tang's finished-dose products in part because the company's factory output is reproducible. The Tianjin AI project extends that reproducibility upstream, into the raw-herb decoction that is still the most common delivery format in Chinese hospitals.

What the AI diagnostic analyzer does in practice

At the World Intelligence Expo in Tianjin on 31 May 2026, an instrument on the exhibition floor drew a steady queue of foreign delegates who wanted to be scanned. The device uses computer vision to capture tongue colour, coating, shape, and facial features (sub-lingual vein distension, peri-orbital hue, complexion), then runs those features through a trained model that outputs a TCM constitution classification (the standard nine-type taxonomy: balanced, qi-deficient, yang-deficient, yin-deficient, phlegm-dampness, damp-heat, blood-stasis, qi-stagnation, special-constitution) plus a short list of dietary and lifestyle recommendations. Total time: a few seconds. No needles, no blood draw, no questionnaire.

For a Chinese patient walking into a tertiary hospital's TCM department, this is not a replacement for the four diagnostic methods (inspection, listening/smelling, inquiry, palpation) that a senior TCM physician performs. The analyzer is a triage tool — it filters the people whose constitution clearly points toward one pattern, so the physician can spend the consultation time on the differential. For an international patient who has never seen a TCM doctor, the analyzer is an entry ramp: it produces a Chinese-medicine vocabulary of their own body that they can take to the consultation. The physician then has a head start on the conversation that might otherwise take 30 minutes of translation and explanation.

Tianjin municipal health authorities have not yet published a price for an AI analyzer consultation at public hospitals. The hardware is in pilot deployment at three Tianjin tertiary hospitals (Tianjin University of Traditional Chinese Medicine First Affiliated Hospital, Tianjin Medical University General Hospital, and Tianjin People's Hospital), with a public rollout expected by Q4 2026.

How Da Ren Tang's product line reaches 47 countries

Da Ren Tang's international distribution is the practical proof point for the modernization thesis. Over twelve years, more than 500 of its products — finished pills, capsules, granules, oral liquids, and external plasters — have been registered in 47 countries and regions as health supplements, food additives, or dietary supplements. The distribution leans heavily on three corridors:

• Southeast Asia (Malaysia, Singapore, Thailand, Indonesia) — finished-dose products under the "health supplement" regulatory category; available in chain pharmacies and TCM clinics.
• European Union — botanical-substance registrations via the Traditional Herbal Medicinal Products Directive (2004/24/EC); narrower product list but a path that bypasses full pharmaceutical licensing for traditional indications.
• North America (US + Canada) — dietary-supplement registration through the FDA / Health Canada frameworks; products are sold as supplements, not drugs, and claims are limited to structure-function language.

For international patients considering a trip to a Chinese hospital for TCM treatment, Da Ren Tang's footprint is the practical entry point: their local physician in Singapore or Berlin can prescribe or recommend Da Ren Tang products for follow-up care after the China-based consultation, and the patient continues the regimen at home with the same manufacturer that produced the hospital-grade herbs.

Where this fits in the broader TCM modernization push

Zhang frames the Tianjin project as the third industrial transition for TCM. The first was mechanisation and electrification in the 1970s and 1980s, when copper pots gave way to stainless steel decoction machines and manual pill-rolling to automated presses. The second was standardisation in the 1990s and 2000s, when the State Administration of TCM introduced Good Manufacturing Practice (GMP) for herbal factories and standardised the composition of flagship formulas such as Liu Wei Di Huang Wan and Xiao Chai Hu Tang. The third, the Tianjin AI push, is what Zhang calls "the digital era" — sensor-controlled production, AI-assisted diagnosis, and full traceability from raw herb to finished dose.

The 2026 National People's Congress work report gives the project explicit policy cover. The report called for "promoting the inheritance and innovation of TCM and facilitating the integration of traditional Chinese and Western medicine." That sentence is the policy hook for state funding, hospital procurement, and provincial health-bureau support. For Zhang's project, it means the 180 million yuan can be matched by municipal subsidies for the AI diagnostic analyzer rollout, and the participating tertiary hospitals can include AI-TCM consultations in their insurance billing schedules once the pilot data lands.

International patients are not the headline target audience for these upgrades — Chinese domestic patients are — but the spillover is real. Hospitals that adopt the AI decoction robots for in-patient TCM prescriptions (a common adjuvant alongside chemotherapy, post-stroke rehabilitation, and chronic pain management) raise the quality floor for every prescription dispensed, including the ones written for foreign patients on the international patient floor.

What this means for an international patient planning a TCM visit

The Tianjin modernization is most relevant for two patient groups. The first is the chronic-disease patient who has cycled through conventional medicine without resolution — the Dawood profile of hypertension that has not responded to standard antihypertensives. For these patients, a Tianjin tertiary hospital TCM consultation (typically 60-90 minutes for a first visit, including tongue-and-pulse diagnosis plus prescription writing) can be paired with the AI analyzer to compress the assessment. The second is the post-treatment patient — someone who has completed chemotherapy, surgery, or another Western intervention and is looking for an integrated regimen to manage side effects, prevent recurrence, or rebuild strength. Zhang specifically cited diabetes as a model: Western medicine is highly effective at lowering blood sugar, but after five or six years, microvascular complications emerge. TCM herbs, layered onto standard antidiabetic drugs, can delay or prevent those complications, with positive feedback from many patients in Zhang's own clinical cohort.

For both groups, the practical access path runs through one of two channels: (a) the international patient department of a Tianjin tertiary hospital (Tianjin University of Traditional Chinese Medicine First Affiliated Hospital is the flagship TCM specialty center), or (b) the outbound consultation programs that Da Ren Tang and similar groups run in 47 partner countries. Either route produces a written TCM diagnosis and prescription; the patient then either fills it in Tianjin at the hospital pharmacy or sources equivalent formulas through a registered Da Ren Tang distributor at home. The cost of a comprehensive TCM consultation in Tianjin at a tertiary public hospital runs roughly RMB 300-800 (US$42-110) for the physician visit, with herbal prescriptions additional.

What to watch in the next 12 months

Three signals will tell you whether the Tianjin modernization is the start of a sector-wide rollout or a one-off demonstration. First, the AI diagnostic analyzer pilot data from the three Tianjin tertiary hospitals — when Q4 2026 results are published, the question is whether the analyzer improved diagnostic concordance with senior TCM physicians by a meaningful margin. Second, the 2027 reimbursement decision from the Tianjin Municipal Healthcare Security Administration on whether AI-assisted TCM consultations are covered under the city's basic medical insurance scheme. Third, the international registration pipeline — whether Da Ren Tang's AI-traceability batch data accelerates its EMA and FDA dossier submissions for finished-dose products in 2026-2027.

For the medical tourism sector, the cleaner signal is institutional: how many other Chinese TCM brands follow Da Ren Tang's AI traceability model, and how quickly the AI diagnostic analyzer appears in the international patient department of flagship TCM hospitals outside Tianjin. Guangdong Provincial TCM Hospital, Longhua Hospital Shanghai, and Beijing TCM Hospital are the three most likely next adopters.

Sources: China Daily, "AI used to customise bespoke TCM treatments," 3 July 2026 (syndicated via The Independent, Asia edition); Tianjin Pharmaceutical Da Ren Tang Group press materials; 2026 National People's Congress work report (State Council).